Zytiga is indicated with prednisone or prednisolone for:...the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated...the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with...metastatic castration-resistant prostate cancer (CRPC)….metastatic high-risk castration-sensitive prostate cancer (CSPC).

...the NCCN panel to recommend abiraterone with 5-mg once-daily prednisone as a treatment option with ADT for men with newly diagnosed, M1, castration-naive prostrate cancer...Prostate Cancer: SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA...Prior novel hormone therapy/No prior docetaxel...Other recommended regimens...Abiraterone + dexamethasone

Prostate Cancer: SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA...No prior docetaxel/no prior novel hormone therapy...Preferred regimens...Abiraterone…Abiraterone should be given with concurrent steroid...Prednisone 5 mg orally once daily for the standard formulation...Methylprednisolone 4 mg orally twice daily for the fine-particle formulation (category 2B).

...abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.